News | October 08, 2013

World Molecular Imaging Congress Features Scientific Breakthroughs in Molecular Multimodal Imaging

October 8, 2013 — The World Molecular Imaging Society (WMIS) held its sixth annual congress in Savannah, Ga. Sept. 18-21.  The World Molecular Imaging Congress (WMIC) 2013 featured advancements in molecular multimodal imaging with a focus on discovery, pre-clinical and translational research, highlighting first-in-human studies that drive innovative diagnostics and targeted therapy critical to the implementation of precision medicine.  

“Molecular imaging and targeted therapy are essential to the successful implementation of precision medicine,” said Hedvig Hricak M.D., Ph.D., chairman, radiology; Memorial Sloan-Kettering Cancer Center and one of eight plenary speakers at the WMIC 2013. “The WMIC is a unique international forum for discussing all aspects of molecular imaging research, from an idea to preclinical studies to first-in-human imaging trials. The WMIS is taking the lead in the global discussions of MI and its clinical applications and it is a pleasure and honor to take part in the 2013 WMIS annual meeting."

The program consisted of 168 oral presentations and 35 spotlight presentations emphasizing five categories: Chemistry and Imaging Probes, First-in-Human and Clinical Studies, Preclinical Cell and Tissue Level Studies, Preclinical In Vivo Studies and Technology and Software development.

For more information:

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init